LeMaitre Vascular, Inc.
NASDAQ:LMATMedical - Instruments & Supplies
+$1.60 today
- Market cap
- $1.73B
- Beta
- 0.52
- P/E (TTM)
- 34.3
- EPS (TTM)
- $2.74
- Dividend yield
- 0.96%
Volume 0.22M
Average 0.26M
LMAT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
LeMaitre Vascular, Inc.NASDAQ: LMAT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows, but more slowly than its trailing trend
Q1 FY2026 depreciation & amortization of $2.62M rose 2.8% year over year, behind the +6.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +3.4% a year.
Context
- Depreciation & amortization amounted to 4.2% of revenue in FY2025, down 0.2 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +2.8% toward the trailing-twelve-month pace of +6.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 10.42M USD
- Year-over-year change
- +7.7%
- 4-year CAGR
- -1.5%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.42M | +7.7% |
| FY2024 | 2024-12-31 | 9.67M | +1.6% |
| FY2023 | 2023-12-31 | 9.52M | +0.9% |
| FY2022 | 2022-12-31 | 9.43M | -14.8% |
| FY2021 | 2021-12-31 | 11.07M | — |
Depreciation & Amortization vs competitors
How LMAT compares with its peers on the latest reported figures
- LMAT's LTM Mar 2026 depreciation & amortization of $10.49M is the smallest of the 8 companies compared; the peer median is $136.48M.
- Its year-over-year change of +6.6% is the 2nd highest of 8, against a peer median of -3.4%.
- Depreciation & amortization amounts to 4.1% of revenue for LMAT, versus a peer median of 7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $2.85B | -3.4% | +3.1% | 7.6% | |
| LTM Jun 2026 | $1.41B | +7.5% | +6.4% | 6.7% | |
| LTM Jun 2026 | $181.49M | -33.6% | -8.3% | 7.0% | |
| LTM Sep 2026 | $136.48M | +3.5% | +13.5% | 8.5% | |
| LTM Mar 2026 | $23.35M | -1.6% | +0.0% | 5.1% | |
| LTM Feb 2026 | $23.19M | -13.4% | -4.2% | 7.4% | |
| LTM Jun 2026 | $17.14M | -10.1% | -10.4% | 1.1% | |
| LTM Mar 2026 | $10.49M | +6.6% | +3.4% | 4.1% | |
| Peer median (excluding LMAT) | $136.48M | -3.4% | +0.0% | 7.0% | |
Competitors are the stored peer set for LMAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 26.91M | 20.64M | 30.11M | 44.04M | 57.73M |
| Depreciation & Amortization | 11.07M | 9.43M | 9.52M | 9.67M | 10.42M |
| Deferred Income Tax | 79K | (182K) | 783K | (451K) | 2.31M |
| Stock-Based Compensation | 3.48M | 4.17M | 5.32M | 6.57M | 7.83M |
| Change in Working Capital | (9.96M) | (13.4M) | (11.25M) | (20.1M) | (1.75M) |
| Accounts Receivables | (818K) | (3.53M) | (3.14M) | (6.42M) | (2.95M) |
| Inventory | (5.49M) | (7.42M) | (9.79M) | (10.57M) | (7.22M) |
| Accounts Payables | (1.73M) | 645K | 4.6M | (779K) | 4.2M |
| Other Working Capital | (1.93M) | (3.1M) | (2.92M) | (2.33M) | 4.22M |
| Other Non-Cash Items | 3.53M | 4.72M | 2.28M | 4.4M | 4.71M |
| Operating Cash Flow | 35.1M | 25.38M | 36.75M | 44.12M | 81.25M |
| Capital Expenditures | (4.88M) | (3.23M) | (7.27M) | (6.96M) | (6.78M) |
| Acquisitions (Net) | 0 | 0 | (899K) | 0 | (1.9M) |
| Purchases of Investments | (59.19M) | (8M) | (16.55M) | (277.94M) | (641.33M) |
| Sales of Investments | 3M | 0 | 0 | 84.78M | 585.07M |
| Other Investing Activities | 0 | 858K | 0 | 0 | 0 |
| Investing Cash Flow | (61.08M) | (10.37M) | (24.72M) | (200.12M) | (64.94M) |
| Debt Repayment | (39M) | 0 | 0 | 169.27M | 0 |
| Common Stock Issued | 63.24M | 3.47M | 6.17M | 6.44M | 6.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | (9.34M) | (10.99M) | (12.45M) | (14.38M) | (18.11M) |
| Other Financing Activities | (1.2M) | (1.71M) | (853K) | (3.23M) | (3.25M) |
| Financing Cash Flow | 13.7M | (9.23M) | (7.13M) | 158.1M | (14.54M) |
| Effect of Forex Changes | (637K) | (494K) | 230K | (765K) | 864K |
| Net Change in Cash | (12.91M) | 5.28M | 5.14M | 1.34M | 2.63M |
| Free Cash Flow | 30.22M | 22.15M | 29.49M | 37.16M | 74.47M |
LeMaitre Vascular, Inc.
NASDAQ:LMAT
Intrinsic Alpha fair value
Locked
Current Price
$75.58
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.